Key Points The biotech published a readout from a clinical trial of an investigational treatment for a skin disorder. Rezpegaldesleukin did well in its latest atopic dermatitis study. 10 stocks we like better than Nektar Therapeutics › Clinical-stage biotech Nektar Therapeutics (NASDAQ: NKTR) had some encouraging news to report from the lab about one of its investigational medicines on Thursday. As often happens in such circumstances, investors flocked to the stock, and it closed the trading sessio ...